Rizatriptan

Exposed non-exposed, cohort studies

Study Country
Study period
Study design
Data source Exposure definition Non-exposure definition Exposition period Sample size
(exposed/unexposed) Or (case / control)
Remarks Overall risk of bias
Källén (control exposed to ergots)
2011
Sweden
1995 - 2008
population based cohort propective
The Swedish Medical Birth Register Infants born to women who had used Rizatriptan during pregnancy. (This is a subgroup of exposure among the whole exposed group considered in the study). exposed to other treatment, sick
Infants born to women who had used Ergots drugs for migraine during pregnancy. (This is a subgroup of exposure among the whole exposed group considered in the study).
1st trimester 157 / 527 Exposed groups of the whole study: drugs for migraine (ergots or triptans). NA
Pregnant women who attend antenatal clinics in Sweden (which the vast majority do) are interviewed by a midwife and asked about drugs used since the pregnancy started. This interview is usually made before the end of the first trimester (usually between weeks 10 and 12 of pregnancy).
Källén (control unexposed, disease free)
2011
Sweden
1995 - 2008
population based cohort propective
The Swedish Medical Birth Register Infants born to women who had used drugs for migraine (triptans or ergots) during pregnancy. Exposure to Rizatriptan provided and considered as a separate subgroup. unexposed, disease free
Infants born to women who did not use drugs for migraine.
1st trimester 157 / 1229901 Exposed groups of the whole study: drugs for migraine (ergots or triptans). 1229901= Total number of infants (n=1233228) - Number of infants whose mother used drugs for migraine in 1st trimester (n=3327) NA
Pregnant women who attend antenatal clinics in Sweden (which the vast majority do) are interviewed by a midwife and asked about drugs used since the pregnancy started. This interview is usually made before the end of the first trimester (usually between weeks 10 and 12 of pregnancy).
Nezvalová-Henriksen (Control unexposed, disease free)
2013
Norway
2004 - 2007
population based cohort retrospective
The Medical Birth Registry of Norway (MBRN) database and The Norwegian Prescription Database (NorPD) Rizatriptan prescription redemption during pregnancy ('anytime' or 'during the first trimester' or 'during the second trimester' or 'during the third trimester'). (This is a subgroup of exposure among the whole exposed group considered in the study). unexposed, disease free
Pregnant women did not redeem triptans during the study period (the population comparison group).
1st trimester, 2nd trimester, 3rd trimester, during pregnancy (anytime or not specified) 334 / 178565 Other triptans also studied. NA
The Norwegian Prescription Database (NorPD) was the source of information on the individual triptan prescriptions. The timing of triptan redemption, in gestational weeks, was determined by the number of weeks from the onset of pregnancy to the date the prescription was redeemed.
Nezvalová-Henriksen (Control unexposed, sick)
2013
Norway
2004 - 2007
population based cohort retrospective
The Medical Birth Registry of Norway (MBRN) database and The Norwegian Prescription Database (NorPD) Rizatriptan prescription redemption during pregnancy ('anytime' or 'during the first trimester' or 'during the second trimester' or 'during the third trimester'). (This is a subgroup of exposure among the whole exposed group considered in the study). unexposed, sick
Triptan prescription redemption between 7 and 1 month prior to pregnancy only.
1st trimester, 2nd trimester, 3rd trimester, during pregnancy (anytime or not specified) 334 / 1095 Other triptans also studied. NA
The Norwegian Prescription Database (NorPD) was the source of information on the individual triptan prescriptions. The timing of triptan redemption, in gestational weeks, was determined by the number of weeks from the onset of pregnancy to the date the prescription was redeemed.

Case-control studies

Study Country
Study period
Study design
Data source Case Control Exposition Exposition period Sample size
(exposed/unexposed) Or (case / control)
Remarks Overall risk of bias

Empty. There are no case-control studies available for this drug.

See the method used to produce these results